Boston Scientific (BSX)
NYSE: BSX · Medical Devices · Marlborough, MA
Our rating: Positive
Positive reaffirmed at $43.50, high conviction, November 3, 2026.
Breaks if: Revenue growth decelerates below ten percent year-over-year in either of the next two quarterly filings, or reported free cash flow on a trailing twelve-month basis falls below two-point-five billion dollars — either outcome would indicate the operational momentum underpinning this call has broken and the Positive view should be revisited.
Key figures
| Market value | $60.8B |
|---|---|
| Revenue, last 12 months | $21.1B |
| Net income, last 12 months | $3.5B |
| Free cash flow, last 12 months | $3.3B |
| Price to earnings | 17.4× |
| Free cash flow yield | 5.5% |
| Dividend yield | 0.0% |
| Operating margin | 18.7% |
| Return on equity | 14.3% |
| Beta to the S&P 500 | 0.55 |
| Volatility, annualized | 30.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $5.1B | 1.4% | $0.40 | $868M |
| June 30, 2026 | $5.4B | 7.5% | $0.61 | $1.3B |
| March 31, 2026 | $5.2B | 11.6% | $0.90 | $171M |
| December 31, 2025 | $5.3B | 15.9% | $0.45 | $1.0B |
| September 30, 2025 | $5.1B | 20.3% | $0.51 | $1.2B |
| June 30, 2025 | $5.1B | 22.8% | $0.53 | $1.1B |
| March 31, 2025 | $4.7B | 20.9% | $0.45 | $354M |
| December 31, 2024 | $4.6B | 22.4% | $0.38 | $1.2B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $5.77B: Claude 18%, Gemini 25%, Mistral 30%
- Diluted earnings per share are at least $0.45: Claude 35%, Gemini 55%, Mistral 50%
- Free cash flow for the quarter is at least $1.01B: Claude 42%, Gemini 75%, Mistral 65%
13 ledger entries and 36 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.